Cover Image
市場調查報告書

全球肽疫苗市場 & 臨床實驗平台的展望

Global Peptide Vaccine Market & Clinical Pipeline Outlook 2020

出版商 KuicK Research 商品編碼 366083
出版日期 內容資訊 英文 300 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球肽疫苗市場 & 臨床實驗平台的展望 Global Peptide Vaccine Market & Clinical Pipeline Outlook 2020
出版日期: 2016年08月11日 內容資訊: 英文 300 Pages
簡介

本報告提供全球肽疫苗市場相關調查分析,概要,機制,癌症免疫療法,市場動態,未來預測,臨床實驗平台等系統性資訊。

第1章 肽疫苗:次單元疫苗

第2章 肽疫苗的需求

  • 為何是肽 - 較好
  • 肽疫苗 V/S 傳統疫苗

第3章 肽疫苗的分類

  • 獲得來源為基礎的分類
  • 期間為基礎的分類
  • 表位為基礎的分類

第4章 肽疫苗的設計 & 製造

  • 合成肽疫苗
  • 肽抗原的選擇
  • 肽抗原的創造
  • 肽疫苗的化學合成

第5章 肽疫苗的機制

  • 免疫反應的簡介
  • 肽疫苗的遞送系統
  • 多抗原肽 (MAP) 系統

第6章 使用肽疫苗的癌症免疫療法

  • 作為腫瘤抗原的肽
  • 肽疫苗接種的免疫療法
  • 肽疫苗的治療評估
    • 前列腺癌
    • 乳癌
    • 胃癌
    • 肺癌
    • 胰臟癌

第7章 全球肽疫苗市場概要

  • 肽疫苗:有很長的安全未來嗎?
  • 肽專利的考察
  • 肽疫苗開發平台概要

第8章 全球肽疫苗市場動態

  • 促進參數
    • Peptidomics
    • 疫苗研究的進步
    • 強力的臨床實驗平台
    • 癌症治療的生技藥品的登場
  • 商業化的課題 & 改良
    • 資金 & 法律的問題
    • 設計 & 製造的課題
    • 給藥途徑
    • 肽藥效學 & 藥物動力學

第9章 全球肽疫苗市場上未來展望

第10章 全球肽疫苗臨床實驗平台:各企業、症狀、相位

  • 研究階段
  • 前臨床階段
  • 第一階段
  • 第一階段/第二階段
  • 第二階段
  • 第三階段

第11章 開發中止/中斷的肽疫苗的臨床實驗平台:各企業、症狀、相位

  • 沒有開發報告
  • 中止
  • 市場撤退
  • 中斷

第12章 競爭情形

  • AFFiRiS
  • AlerGenetica
  • Anergis
  • Antigen Express
  • Apitope Technology
  • Araclon Biotech
  • Artificial Cell Technologies
  • Benovus Bio
  • Bionor Pharma
  • Circassia
  • Celgene Corporation
  • Galena Biopharma
  • Immatics biotechnologies
  • Immune Design
  • ImmunoCellular Therapeutics
  • Invectys
  • ISA Pharmaceuticals
  • Lytix Biopharma
  • Medinet
  • Spotlight Innovation (Memcine Pharmaceuticals)
  • Merck Serono
  • OncoTherapy Science
  • Peptech
  • Peptinov
  • PeptiVir
  • Pharmasyntez
  • Renaptys Vaccines
  • 大日本住友製藥
  • TapImmune
  • Targovax
  • Vaxon Biotech

圖表

目錄

The outline of human vaccines had an incredible impact on global health system which resulted in intense reduction of mortality and morbidity caused by numerous diseases. Vaccines have led to some of the greatest public health achievements ever, including the eradication of naturally occurring smallpox from the globe and the near eradication of polio. This prophylaxis had a long journey through various roads and tunnels to become the humanities' key achievement. Despite of the fact, that its mechanism of action remained unclear for centuries. New vaccines coined up in nineteenth century and after the expanded studies of infectious diseases and processed microorganism vaccination has become an intensive subject to be studied. By all the new advances towards the discovery and understanding of various diseases, our species was able to find a way to eradicate them.

In recent years peptides have emerged as the considerable vaccine candidate owning to their simple and cost efficient production & development process. Peptides are recognized for being highly selective and efficacious and, at the same time, relatively safe and well tolerated. Given their attractive pharmacological profile and intrinsic properties, peptides represent an excellent starting point for the design of novel therapeutics. Several peptide vaccines are now being designed and are encountering phase I and phase II clinical trials.

Peptide vaccines include one or more short or long amino acids sequences, as an antigen combined with a vaccine adjuvant. Thus they fall in the broad category of defined antigen vaccines, along with the vaccines using proteins, protein sub units, DNA and RNA. They remain the most immunogenic approaches based on the measures of T-cell responses. Peptide immunogenicity is influenced by the way in which peptides are presented to the immune system, underscoring the need for multifunctional delivery systems that couple antigen and adjuvant into a single construct.

Cancer immunotherapy by peptide vaccines is one of most emerging and significant segment that could help pharmaceutical companies to generate more revenues and help patients to alleviate their medical condition. Peptide vaccine for treatment of metastatic prostate cancer has been introduced in global market. This segment has tendency towards clinical trials as compared to marketed products. Most of the novel products are at different stages of clinical trials which would be introduced in global market in coming years. Biomarkers like Melanoma-Associated Antigen 1 (MAGE-1) for melanoma cancer vaccine and NY-ESO-1 for lung cancer are being developed. Their development requires state-of-art technology due to which they are still not available in market. But confidently these drugs are going to overcome the all hurdles and will become the best suitable candidates in drug market.

A persistent theme in recent peptide based therapeutics is to trigger adaptive antigen specific responses. The next generation drugs will be designed to deliver defined antigenic peptides, target DCs and PRR agonists. Combinations of carrier with TLR agonists provide new advantages of their cytokine production in enhancing immune response.This is already evident that in ongoing clinical trials that the benefits of using such vaccines will be large however safety concerns with diseases like cancer and HIV are still under critical observations. With the growing knowledge of immunological mechanism of adjuvant action, including identifying the role of specific signaling pathways peptide based vaccines are going to become more attractive and more effective segment of therapeutics.

Although, the opinions of experts in this field are mixed, it is likely that with new product approvals and advanced research, the field of active peptide immunotherapy is self-assured for dramatic growth in the coming years. Using the gained knowledge and history of passive immunotherapy development as guiding tool, the peptides will revolutionize the market with modern treatment of varied diseases by the means of peptides vaccines.

"Global Peptide Vaccine Market & Clinical Pipeline Outlook 2020" Report Highlights:

  • Introduction & Classification of Peptide Vaccines
  • Designing & Production of Peptide Vaccine
  • Mechanism of Peptide Vaccine
  • Cancer Immunotherapy with Peptide Vaccine
  • Global Peptide Vaccine Clinical Pipeline by Company, Indication & Phase
  • Global Peptide Vaccine Clinical Pipeline: 97 Vaccine
  • Majority vaccines in Preclinical Phase: 28 Vaccines
  • Global Peptide Vaccine Market Future Prospects

Table of Contents

1. Peptide Vaccine: A Prologue to Sub-Unit Vaccines

  • 1.1 Introduction
  • 1.2 Glimpse of Antiquity

2. Need of Peptide Vaccines

  • 2.1 Why Peptides - More Desirable
  • 2.2 Peptide Vaccines V/S Traditional Vaccines

3. Classification of Peptide Vaccines

  • 3.1 On the Basis of Sources Obtained
  • 3.2 On the Basis of Length
  • 3.3 On the Basis of Epitopes

4. Designing & Production of Peptide Vaccine

  • 4.1 Synthetic Peptide Vaccine
  • 4.2 Selection of Peptide Antigen
  • 4.3 Construction of Peptide Antigen
  • 4.4 Chemical Synthesis of Peptide Vaccine
    • 4.4.1 Solution Phase Synthesis (SPS)
    • 4.4.2 Solid Phase Peptide Synthesis (SPPS)

5. Mechanism of Peptide Vaccine

  • 5.1 Induction of Immune Response
    • 5.1.1 Factors Affecting T-Cell Stimulation
    • 5.1.2 Factors Affecting B-cell Stimulation
    • 5.1.3 Factors Affecting T-helper Cells
  • 5.2 Delivery System for Peptide Vaccines
    • 5.2.1 Immunostimulatory Adjuvants
    • 5.2.2 Vaccine Delivery System
  • 5.3 Multiple Antigen Peptide System (MAP)
    • 5.3.1 Use of MAP for Foot-and-Mouth Disease

6. Cancer Immunotherapy with Peptide Vaccine

  • 6.1 Peptides as Tumor Antigens
  • 6.2 Immunotherapy with Peptide Vaccination
  • 6.3 Therapeutic Evaluation of Peptide Vaccine
    • 6.3.1 Prostate Cancer
    • 6.3.2 Breast Cancer
    • 6.3.3 Gastric Cancer
    • 6.3.4 Lung Cancer
    • 6.3.5 Pancreatic Cancer

7. Global Peptide Vaccine Market Overview

  • 7.1 Peptide Vaccine - Does have Long & Secure Future?
  • 7.2 Peptide Patents Insights
  • 7.3 Peptide Vaccine Pipeline Overview

8. Global Peptide Vaccine Market Dynamics

  • 8.1 Accelerative Parameters
    • 8.1.1 Peptidomics
    • 8.1.2 Advances in Vaccine Research
    • 8.1.3 Stronger Clinical Pipeline
    • 8.1.4 Emergence of Biologics in Cancer Therapy
  • 8.2 Commercialization Challenges & Modifications
    • 8.2.1 Funding & Legal Issues
    • 8.2.2 Designing & Manufacturing Challenges
    • 8.2.3 Route of Administration
    • 8.2.4 Peptide Pharmacodynamics & Pharmacokinetics

9. Global Peptide Vaccine Market Future Perspectives

10. Global Peptide Vaccine Clinical Pipeline by Company, Indication & Phase

  • 10.1 Research
  • 10.2 Preclinical
  • 10.3 Phase-I
  • 10.4 Phase-I/II
  • 10.5 Phase-II
  • 10.6 Phase-III

11. Discontinued & Suspended Peptide Vaccine Clinical Pipeline by Company, Indication & Phase

  • 11.1 No Development Reported
  • 11.2 Discontinued
  • 11.3 Market Withdrawal
  • 11.4 Suspended

12. Competitive Landscape

  • 12.1 AFFiRiS
  • 12.2 AlerGenetica
  • 12.3 Anergis
  • 12.4 Antigen Express
  • 12.5 Apitope Technology
  • 12.6 Araclon Biotech
  • 12.7 Artificial Cell Technologies
  • 12.8 Benovus Bio
  • 12.9 Bionor Pharma
  • 12.10 Circassia
  • 12.11 Celgene Corporation
  • 12.12 Galena Biopharma
  • 12.13 Immatics biotechnologies
  • 12.14 Immune Design
  • 12.15 ImmunoCellular Therapeutics
  • 12.16 Invectys
  • 12.17 ISA Pharmaceuticals
  • 12.18 Lytix Biopharma
  • 12.19 Medinet
  • 12.20 Spotlight Innovation (Memcine Pharmaceuticals)
  • 12.21 Merck Serono
  • 12.22 OncoTherapy Science
  • 12.23 Peptech
  • 12.24 Peptinov
  • 12.25 PeptiVir
  • 12.26 Pharmasyntez
  • 12.27 Renaptys Vaccines
  • 12.28 Sumitomo Dainippon Pharma
  • 12.29 TapImmune
  • 12.30 Targovax
  • 12.31 Vaxon Biotech

List of Figures

  • Figure 1-1: History of Vaccines
  • Figure 2-1: Peptides - Amino Acid & Proteins
  • Figure 2-2: Diversification of Vaccines
  • Figure 2-3: Sub-Unit Vaccines V/S Traditional Vaccines
  • Figure 3-1: Classification of Peptide Vaccine by Source
  • Figure 3-2: Classification on Basis of Length
  • Figure 3-3: On the Basis of Epitopes
  • Figure 4-1: Synthetic Peptide Manufacturing Process
  • Figure 4-2: Selection of Synthetic Immunogenic Constructs
  • Figure 4-3: Solid phase Peptide Synthesis v/s Solution Phase Technique.
  • Figure 4-4: Fmoc Cleavage
  • Figure 4-5: Boc Cleavage
  • Figure 5-1: Mechanism of Immune Activation of CD4+ and CD8+ T-Cells
  • Figure 5-2: Delivery System Pathways by Adjuvants
  • Figure 5-3: Liposome & the Modes of Chemically Different Antigen Incorporation.
  • Figure 6-1: TAAs on the Basis of Tissue Distribution
  • Figure 6-2: Vaccination via Peptide Loaded Dendritic Cells
  • Figure 6-3: Mechanism of Action of Sipuleucel-T
  • Figure 6-4: Use of HER-Vaxx Antigen for Production of Antibodies
  • Figure 6-5: Peptides Applied in Treating Cancer
  • Figure 7-1: Global Peptide Drug Market (US$ Billion), 2014-2020
  • Figure 7-2: Approved Peptide Drugs
  • Figure 7-3: Global - Peptide Vaccine Clinical Pipeline by Phase (%), 2016
  • Figure 7-4: Global - Peptide Vaccine Clinical Pipeline by Phase (Numbers), 2016
  • Figure 7-5: Global - Active & Suspended Peptide Vaccine Clinical Pipeline by Phase (%), 2016
  • Figure 7-6: Global - Active & Suspended Peptide Vaccine Clinical Pipeline by Phase (Numbers), 2016
  • Figure 8-1: Global - Peptide Market Favorable Parameters
  • Figure 8-2: Global - Peptide Vaccine Market Commercialization Challenges
  • Figure 8-3: Routes of Administration
  • Figure 12-1: Anergis - Clinical Pipeline
  • Figure 12-2: Apitope Technology - Clinical Pipeline
  • Figure 12-3: Benovus Bio - Clinical Pipeline
  • Figure 12-4: Bionor Pharma - Clinical Pipeline
  • Figure 12-5: Circassia - Clinical Pipeline
  • Figure 12-6: Celgene - Clinical Pipeline
  • Figure 12-7: Galena Biopharma - Clinical Pipeline
  • Figure 12-8: Immatics Biotechnologies - Clinical Pipeline
  • Figure 12-9: Immune Design - Clinical Pipeline
  • Figure 12-10: ImmunoCellular Therapeutics - Clinical Pipeline
  • Figure 12-11: Invectys - Clinical Pipeline
  • Figure 12-12: ISA Pharmaceuticals - Clinical Pipeline
  • Figure 12-13: Lytix Biopharma - Clinical Pipeline
  • Figure 12-14: Merck Serono - Clinical Pipeline
  • Figure 12-15: Onco Therapy Science - Clinical Pipeline
  • Figure 12-16: Peptinov - Clinical Pipeline
  • Figure 12-17: Sumitomo Dainippon Pharma - Clinical Pipeline
  • Figure 12-18: Tapimmune - Clinical Pipeline
  • Figure 12-19: Targovax - Clinical Pipeline
  • Figure 12-20: Vaxon Biotech - Clinical Pipeline
Back to Top